Intercytex - Wikipedia, the free encyclopedia
15 Oct 2009 ... In June 2008, Intercytex announced positive results of their Phase II trial for a form of cloning based Hair multiplication technique called ...
http://en.wikipedia.org/wiki/Intercytex...
|
All topics tagged with "intercytex" in Euroscicon Chat forum on ...
Dr. Paul Kemp of Intercytex to speak at 'Future Advances in Regenerative Medicine' meeting ... Nothing else on Nature Network is tagged with "intercytex" . ...
http://network.nature.com/groups/euroscicon/forum/tags/inter...
|
BioSpace - Intercytex Limited News, Search Jobs, Events
Intercytex Group plc Release: VAVELTA(R): Phase II Data Presented at FACE and Commercial Sales Commenced 7/17/2008 4:24:33 PM More. ...
http://www.biospace.com/company_profile.aspx?CompanyId=88352...
|
Forums containing the tag "intercytex" on Nature Network
Topics. Dr. Paul Kemp of Intercytex to speak at 'Future Advances in Regenerative Medicine' meeting. Sitewide. more items tagged "intercytex". Search forums ...
http://network.nature.com/forums/tags/intercytex...
|
Intercytex Limited Completes Recruitment for Phase III Trial of ...
4 Jun 2008 ... Intercytex Group plc (LSE: ICX) the leading developer of regenerative medicine products to restore skin and hair, today announces it has ...
http://www.biospace.com/news_story.aspx?NewsEntityId=99315...
|
Dr. Paul Kemp of Intercytex to speak at 'Future Advances in ...
Dr Paul Kemp, Founder and Chief Scientific Officer of UK-based company Intercytex will be speaking at our 'Future Advances in Regenerative Medicine' meeting ...
http://network.nature.com/groups/euroscicon/forum/topics/148...
|
BioSpace - Intercytex Group plc News, Search Jobs, Events
Intercytex Group plc Announces Temporary Suspension of Trading of Shares on ... Intercytex Group plc to Cut 50% of Jobs to Stay Afloat 1/26/2009 6:46:02 AM ...
http://www.biospace.com/company_profile.aspx?CompanyId=10077...
|
News: Intercytex Wind-Down Continues with Sale of Stem Cell ...
23 Nov 2009 ... Intercytex has sold part of its stem cell therapeutics subsidiary, Axordia, to Pfizer for $750000 in cash, £75000 ($124613) of the total ...
http://www.genengnews.com/news/bnitem.aspx?name=69320169...
|
...
|
News: Intercytex Wind-Down Continues with Sale of Stem Cell ...
23 Nov 2009 ... Failure of Phase III venous leg ulcers candidate, Cyzact, represented final straw for regenerative medicines company.
http://www.genengnews.com/news/bnitem.aspx?name=69320169&tax...
|